Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Benitec Biopharma Ltd ADR

Healthcare US BNTC

12.3USD
0.15(1.23%)

Last update at 2026-06-22T20:00:00Z

Day Range

11.9512.58
LowHigh

52 Week Range

9.8517.15
LowHigh

Fundamentals

  • Previous Close 12.15
  • Market Cap479.23M
  • Volume93360
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-48.29500M
  • Revenue TTM0.00700M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -37.91700M -21.75100M -19.56200M -18.20800M -13.88200M
Minority interest - - - - -
Net income -37.91700M -21.75100M -19.56200M -18.56200M -13.78100M
Selling general administrative 23.43M 6.71M 6.38M 6.65M 6.51M
Selling and marketing expenses - 0.28M - - -
Gross profit -0.39600M -0.34300M 0.07M 0.06M -0.06400M
Reconciled depreciation 0.40M 0.34M 0.38M 0.39M 0.42M
Ebit -41.76500M -21.75100M -19.11100M -17.85400M -13.59600M
Ebitda -41.69567M -21.40800M -18.73000M -17.93300M -13.27900M
Depreciation and amortization 0.07M 0.34M 0.38M -0.07900M 0.32M
Non operating income net other - - - - -
Operating income -41.76500M -22.59800M -19.08100M -17.85400M -13.59600M
Other operating expenses 41.77M 22.60M 19.16M 17.93M 13.65M
Interest expense - 0.90M 0.03M 0.03M -0.00600M
Tax provision - - - - -
Interest income - - - - 0.00600M
Net interest income 3.29M 0.90M -0.03300M -0.03200M -0.00600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.61900M 0.00300M 0.35M -0.10100M
Total revenue 0.00000M 0.22M 0.07M 0.07M 0.06M
Total operating expenses 41.37M 22.25M 19.16M 17.92M 13.53M
Cost of revenue 0.40M 0.34M 0.00000M 0.00900M 0.12M
Total other income expense net 3.85M 0.85M -0.44800M -0.35400M -0.28600M
Discontinued operations - - - - -
Net income from continuing ops -37.91700M -21.75100M -19.56200M -18.20800M -13.88200M
Net income applicable to common shares - - -19.56200M -18.20800M -13.88200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 99.59M 52.21M 4.46M 5.97M 21.38M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.74M 0.58M 1.18M 0.76M 0.81M
Total liab 2.30M 4.96M 4.26M 3.09M 1.37M
Total stockholder equity 97.30M 47.25M 0.20M 2.88M 20.01M
Deferred long term liab - - - - -
Other current liab 1.25M 3.29M 3.70M 0.40M 0.28M
Common stock 0.00200M 0.00100M - 0.00100M 0.00100M
Capital stock 0.00200M 0.00100M 0.00000M 0.00100M 0.00100M
Retained earnings -228.17600M -190.25900M -167.88900M -148.32700M -130.11900M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.12M 0.16M 0.19M
Cash 97.74M 50.87M 2.48M 4.06M 19.77M
Cash and equivalents - - - - -
Total current liabilities 1.80M 4.92M 3.98M 2.53M 1.37M
Current deferred revenue - -1.35100M -1.14000M - -
Net debt -96.89500M -50.58200M -1.91800M -3.25100M -19.55600M
Short term debt 0.35M 0.28M 0.28M 0.25M 0.21M
Short long term debt - - - - -
Short long term debt total 0.85M 0.28M 0.56M 0.81M 0.21M
Other stockholder equity 326.31M 238.40M 168.92M 152.45M 151.58M
Property plant equipment - - 0.61M 0.99M 0.58M
Total current assets 98.52M 51.67M 3.73M 4.82M 20.61M
Long term investments - - - - -
Net tangible assets - - 0.20M 2.88M 20.01M
Short term investments - - - - -
Net receivables 0.03M 0.23M 0.06M 0.00300M 0.03M
Long term debt - - - - -
Inventory - 0.06M 0.01M - -
Accounts payable 0.20M 1.35M 1.14M 1.88M 0.88M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.83900M -0.89200M -0.83000M -1.24500M -1.45500M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.08M 0.09M 0.12M 0.16M 0.19M
Deferred long term asset charges - - - - -
Non current assets total 1.07M 0.54M 0.73M 1.15M 0.77M
Capital lease obligations 0.85M 0.28M 0.56M 0.81M 0.21M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.01800M -0.17900M -0.00100M -0.01300M -0.22100M
Change to liabilities - - 1.36M 1.09M 0.06M
Total cashflows from investing activities -0.01800M -0.17900M -0.00100M -0.01300M -0.22100M
Net borrowings - - - - -
Total cash from financing activities 70.48M 68.03M 16.02M 16.02M 22.52M
Change to operating activities - - -0.59300M -0.05400M -0.07500M
Net income -37.91700M -21.75100M -19.56200M -18.20800M -13.88200M
Change in cash 46.93M 48.44M -1.58600M -15.70800M 9.97M
Begin period cash flow 50.93M 2.49M 4.08M 19.78M 9.80M
End period cash flow 97.86M 50.93M 2.49M 4.08M 19.77M
Total cash from operating activities -23.58800M -19.40300M -18.01200M -15.89900M -12.83200M
Issuance of capital stock 30.46M 73.92M 17.88M 0.00000M 25.75M
Depreciation 0.40M 0.34M 0.38M 0.39M 0.42M
Other cashflows from investing activities - - - - -
Dividends paid - 0.62M - - -
Change to inventory - - - - -
Change to account receivables 0.20M -0.17600M -0.05000M 0.00100M 0.03M
Sale purchase of stock - - - - -
Other cashflows from financing activities - -2.85400M -1.86900M -0.01300M -3.22800M
Change to netincome - - 0.46M 0.88M 0.62M
Capital expenditures 0.02M 0.18M 0.00100M 0.01M 0.22M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.72900M 1.17M 0.71M 1.04M 0.00800M
Stock based compensation 17.43M 0.83M 0.45M 0.87M 0.63M
Other non cash items -0.76400M 0.00100M 0.72M 0.01000M -0.01600M
Free cash flow -23.60600M -19.58200M -18.01300M -15.91200M -13.05300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BNTC
Benitec Biopharma Ltd ADR		 0.15 1.23% 12.30 - - 2770.13 2.58 10457.68 850.87
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Benitec Biopharma Ltd ADR

3940 Trust Way, Hayward, CA, United States, 94545

Key Executives

Name Title Year Born
Dr. Jerel A. Banks M.D., Ph.D. Exec. Chairman & CEO 1975
Ms. Megan Joan Boston BComm, CA, Dip., GAICD Exec. Director 1972
Mr. Bryan Dulhunty Chief Financial Officer NA
Dr. Michael Graham Head of Discovery & Founding Scientist NA
Dr. Craig Lewis Chief Medical Adviser NA
Dr. Claudia Kloth Sr. VP of Manufacturing NA
Dr. Jerel A. Banks M.D., Ph.D. Executive Chairman & CEO 1975
Ms. Megan Joan Boston BComm, CA, Dip., GAICD Executive Director 1972
Dr. Claudia Kloth Senior Vice President of Manufacturing NA
Dr. Jerel A. Banks M.D., Ph.D. Executive Chairman & CEO 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.